JPMorgan Chase & Co. Buys 930,701 Shares of Haleon plc (NYSE:HLN)

JPMorgan Chase & Co. grew its position in shares of Haleon plc (NYSE:HLN - Free Report) by 18.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,014,903 shares of the company's stock after acquiring an additional 930,701 shares during the quarter. JPMorgan Chase & Co. owned about 0.13% of Haleon worth $57,382,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in shares of Haleon by 41.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 203,583 shares of the company's stock worth $2,154,000 after acquiring an additional 59,719 shares during the last quarter. Benjamin Edwards Inc. bought a new position in shares of Haleon in the 3rd quarter worth about $805,000. Hilltop Holdings Inc. bought a new position in Haleon in the third quarter worth about $133,000. HighTower Advisors LLC boosted its position in Haleon by 27.2% during the 3rd quarter. HighTower Advisors LLC now owns 350,795 shares of the company's stock valued at $3,701,000 after purchasing an additional 74,970 shares during the period. Finally, IHT Wealth Management LLC boosted its holdings in shares of Haleon by 56.7% during the third quarter. IHT Wealth Management LLC now owns 34,809 shares of the company's stock valued at $370,000 after acquiring an additional 12,595 shares during the period. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Price Performance

Shares of NYSE:HLN traded up $0.35 during midday trading on Wednesday, reaching $9.70. The company's stock had a trading volume of 25,615,699 shares, compared to its average volume of 6,871,876. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market capitalization of $43.80 billion, a P/E ratio of 28.51, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a fifty-two week low of $7.99 and a fifty-two week high of $10.80. The business's fifty day simple moving average is $10.03 and its 200-day simple moving average is $9.83.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. As a group, equities research analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The business also recently announced a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This is a positive change from Haleon's previous -- dividend of $0.05. This represents a yield of 1.6%. Haleon's dividend payout ratio is presently 58.97%.

Analyst Upgrades and Downgrades

HLN has been the subject of several recent analyst reports. HSBC reissued a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Morgan Stanley cut Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. Sanford C. Bernstein cut shares of Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Six analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Haleon presently has an average rating of "Hold" and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.